<h4>Background</h4>Progesterone receptor antagonists such as mifepristone have emerged as candidates for breast cancer prevention, particularly in high-risk populations such as BRCA1/2 pathogenic variant carriers. This evidence concerns the gene BRCA1 and breast carcinoma.